Insider Selling: Medpace (NASDAQ:MEDP) CEO Sells $10,655,987.10 in Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 17,610 shares of the firm’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $605.11, for a total transaction of $10,655,987.10. Following the completion of the transaction, the chief executive officer directly owned 615,802 shares of the company’s stock, valued at $372,627,948.22. This represents a 2.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Medpace Trading Down 0.6%

NASDAQ MEDP opened at $578.50 on Friday. The firm’s fifty day moving average price is $536.23 and its two-hundred day moving average price is $492.35. Medpace Holdings, Inc. has a 1 year low of $373.00 and a 1 year high of $677.90. The firm has a market capitalization of $16.15 billion, a P/E ratio of 33.91, a price-to-earnings-growth ratio of 2.60 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating analysts’ consensus estimates of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The firm had revenue of $707.33 million during the quarter, compared to analysts’ expectations of $689.51 million. During the same quarter last year, the company posted $3.10 earnings per share. The company’s revenue for the quarter was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, research analysts anticipate that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

Institutional Trading of Medpace

Several hedge funds and other institutional investors have recently bought and sold shares of MEDP. BlackRock Inc. acquired a new position in shares of Medpace during the 2nd quarter worth approximately $1,323,047,000. AQR Capital Management LLC raised its position in shares of Medpace by 31.6% in the fourth quarter. AQR Capital Management LLC now owns 1,349,703 shares of the company’s stock valued at $758,061,000 after buying an additional 324,293 shares in the last quarter. Wasatch Advisors LP boosted its stake in shares of Medpace by 14.0% in the second quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock valued at $296,853,000 after buying an additional 116,354 shares during the period. Geode Capital Management LLC grew its position in Medpace by 3.8% during the fourth quarter. Geode Capital Management LLC now owns 667,298 shares of the company’s stock worth $374,836,000 after buying an additional 24,625 shares in the last quarter. Finally, Invesco Ltd. grew its position in Medpace by 18.9% during the third quarter. Invesco Ltd. now owns 537,407 shares of the company’s stock worth $276,313,000 after buying an additional 85,517 shares in the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. BMO Capital Markets lifted their price target on Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a report on Friday, July 24th. Barclays set a $600.00 price objective on Medpace in a research report on Thursday, July 23rd. Royal Bank Of Canada lifted their target price on Medpace from $484.00 to $692.00 and gave the stock an “outperform” rating in a research note on Friday, July 24th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a $535.00 target price on shares of Medpace in a report on Thursday, July 23rd. Finally, Wall Street Zen cut Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Three investment analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. According to data from MarketBeat, Medpace presently has an average rating of “Hold” and an average target price of $584.18.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.